Sep. 7 at 1:48 PM
$IMMX Worth upping this excellent post.
@bnglao24, agree on the mechanics.
One thing worth adding, as Sept isn't an interim in any regulatory sense (Enrollment closed in March, nothing can be stopped or changed, no committee is reviewing anything): it's a corporate update, and the company has full latitude on how to frame it.
So expect the presentation to work the angles: CR in the mature subset, VGPR/CR aggregate for the rest, MRD trajectory, organ responses, low progression count. All accurate, all favorable.
The CR number that carries regulatory weight is the IRC-adjudicated one at 1-year follow-up, due by end of March 2027. That's the BLA dataset. Sept is a sentiment event.
Your three metrics are the right ones. I'd add: watch safety across pts 21-45. That's the differentiator vs bispecifics, and it's where a surprise would actually matter.
